# Aflibercept as Adjunctive Treatment for Filtration Surgery in Neovascular Glaucoma

> **NCT04970251** · NA · COMPLETED · sponsor: **Siriraj Hospital** · enrollment: 5 (actual)

## Conditions studied

- Intraocular Pressure
- Neovascular Glaucoma
- Vascular Endothelial Growth Factor Overexpression
- Glaucoma Secondary to Eye Inflammation

## Interventions

- **DRUG:** Aflibercept Ophthalmic

## Key facts

- **NCT ID:** NCT04970251
- **Lead sponsor:** Siriraj Hospital
- **Sponsor class:** OTHER
- **Phase:** NA
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2018-11-01
- **Primary completion:** 2021-03-31
- **Final completion:** 2021-03-31
- **Target enrollment:** 5 (ACTUAL)
- **Last updated:** 2021-07-21


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT04970251

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT04970251, "Aflibercept as Adjunctive Treatment for Filtration Surgery in Neovascular Glaucoma". Retrieved via AI Analytics 2026-06-02 from https://api.ai-analytics.org/clinical/NCT04970251. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*